Managing multiple myeloma patients with del(17p) Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, outlines treatment options for patients with multiple myeloma with 17p deletion, highlighting key clinical trials. Numerous studies have demonstrated that this patient population has a poorer prognosis compared to other patients with multiple myeloma. The HOVON-65/GMMG-HD4 […]

Read More

Hear what is Multiple Myeloma | Dr. Amrita Chakrabarty |Hematologist | Myeloma, also known as multiple myeloma, is a common blood cancer arising from plasma cells. Plasma cells are a type of white blood cells that produce antibodies, also called immunoglobulins, to help fight infection. When the plasma cells become malignant, they grow out of […]

Read More